View Older Stories View More Recent Stories

Dec 13, 2019 04:02PM Horizon Pharma (HZNP) Confirms FDA Advisory Committee Votes Unanimously to Support Use of Teprotumumab for Treatment of Thyroid Eye Disease
Dec 13, 2019 04:01PM FDA Advisory Committee Votes Unanimously to Support the Use of Teprotumumab for the Treatment of Thyroid Eye Disease (TED)
Dec 13, 2019 07:01AM Horizon Pharma (HZNP) Trading Halted Today for FDA DODAC Meeting to Discuss Teprotumumab for Thyroid Eye Disease
Dec 13, 2019 07:00AM Horizon Therapeutics plc Trading Halted Today; FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting to Discuss Teprotumumab for Thyroid Eye Disease
Dec 9, 2019 08:00AM Horizon Therapeutics plc to Present at the 38th Annual J.P. Morgan Healthcare Conference
Nov 22, 2019 08:00AM Horizon Therapeutics plc Opens New Manufacturing and R&D Facility in South San Francisco
Nov 21, 2019 08:00AM Horizon Therapeutics plc Launches New Online Community Connecting People Living with Thyroid Eye Disease and Urging them to “Listen to Your Eyes”
Nov 14, 2019 09:30AM FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Workplaces for Parents List
Nov 13, 2019 04:15PM Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
Nov 11, 2019 08:11AM Horizon Pharma (HZNP) Says Data from Uncontrolled Gout Case Series Supports Immunomodulation with KRYSTEXXA Strategy to Optimize Treatment Outcomes
Nov 11, 2019 08:00AM Data from Uncontrolled Gout Case Series Supports Immunomodulation with KRYSTEXXA® (pegloticase injection) Strategy to Optimize Treatment Outcomes
Nov 8, 2019 09:30AM The Chicago Tribune Names Horizon Therapeutics plc a 2019 Top Workplace
Nov 6, 2019 07:00AM Horizon Therapeutics plc Reports Strong Third-Quarter 2019 Results
Nov 5, 2019 08:00AM Horizon Therapeutics plc Brings Gout-Kidney Link into Focus during American Society of Nephrology (ASN) Kidney Week 2019
Nov 4, 2019 08:30AM Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presented During ACR Annual Meeting
Oct 31, 2019 10:00AM Integrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effects of Thyroid Eye Disease, Including Eye Bulging, Double Vision and Quality of Life
Oct 24, 2019 11:15AM Horizon Therapeutics plc Named One of the Most Innovative Companies by Crain’s Chicago Business
Oct 24, 2019 08:00AM New Combined Data from the Phase 2 and Phase 3 Teprotumumab Clinical Trials to be Presented during the American Thyroid Association Annual Meeting
Oct 17, 2019 09:00AM FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Small & Medium Workplaces List for Fourth Consecutive Year
Oct 17, 2019 08:07AM Horizon Pharma (HZNP) Begins PROTECT Trial Evaluating KRYSTEXXA (pegloticase injection)
Oct 17, 2019 08:00AM Horizon Therapeutics plc Initiates PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) to Improve Management of Uncontrolled Gout for Adults with a Kidney Transplant
Oct 11, 2019 12:33PM Horizon Pharma (HZNP) Reports New Data from Teprotumumab Ph. 3 OPTIC Study Showing 'Significant Benefit' on Effects of Active TED
Oct 11, 2019 12:30PM New Data from Teprotumumab Phase 3 OPTIC Study Shows Significantly Reduced Double Vision and Improved Quality of Life for People with Active Thyroid Eye Disease
Oct 10, 2019 09:00AM For World Sight Day, Horizon and Prevent Blindness Are Calling on the Thyroid Eye Disease (TED) Community to Put “Vision First”
Oct 9, 2019 08:00AM Horizon Therapeutics plc to Release Third-Quarter 2019 Financial Results and Host Webcast on Nov. 6, 2019
Oct 8, 2019 08:00AM New Data Insights from the Phase 3 Teprotumumab Trial (OPTIC) to be Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Scientific Symposium
Oct 3, 2019 08:00AM Horizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption
Sep 9, 2019 08:03AM Horizon Pharma (HZNP) Announces FDA has Granted Priority Review of Teprotumumab BLA for Treatment of Active TED
Sep 9, 2019 08:00AM Horizon Therapeutics plc Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)
Aug 28, 2019 04:30PM Horizon Therapeutics plc Names Andy Pasternak Executive Vice President, Chief Business Officer
Aug 19, 2019 09:00AM American Journal of Ophthalmology (AJO) Publishes Review Highlighting Lack of Treatments for Active Thyroid Eye Disease (TED)
Aug 19, 2019 08:00AM Horizon Therapeutics plc to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference
Aug 14, 2019 08:00AM Horizon Therapeutics plc Collaborates with Rare Disease Advocates to Elevate Resources and Shared Experiences Through Launch of #RAREis™ Community Website
Aug 7, 2019 07:00AM Horizon Therapeutics plc Reports Strong Second-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance
Aug 1, 2019 10:45AM Horizon Therapeutics plc Announces Teprotumumab Expanded Access Program
Aug 1, 2019 08:00AM Horizon Therapeutics plc Appoints Dr. Sue Mahony to Board of Directors
Jul 25, 2019 08:00AM Horizon Therapeutics plc Wins International CSR Excellence Award for Partnership with Perspectives Math and Science Academy
Jul 18, 2019 09:01AM Horizon Pharma (HZNP) Announces U.S. FDA Acceptance of its NDA to Make PROCYSBI Available as Oral Granules in Packets
Jul 18, 2019 09:00AM Horizon Therapeutics plc Announces U.S. FDA Acceptance of its New Drug Application to Make PROCYSBI® (Cysteamine Bitartrate) Available as Oral Granules in Packets
Jul 16, 2019 08:00AM Horizon Therapeutics plc to Release Second-Quarter 2019 Financial Results and Host Webcast on Aug. 7, 2019
Jul 10, 2019 07:02AM Horizon Pharma (HZNP) Reports Submission of Teprotumumab Biologics License Application (BLA) to FDA for Treatment of Active Thyroid Eye Disease
Jul 10, 2019 07:00AM Horizon Therapeutics plc Submits Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)
Jun 27, 2019 09:54AM Eyes on Graves’ Initiative Urges Action for People with Graves’ Disease and Thyroid Eye Disease
Jun 20, 2019 08:04AM Horizon Pharma (HZNP) Commences MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA (pegloticase injection) in Combination with Methotrexate
Jun 20, 2019 08:00AM Horizon Therapeutics plc Initiates MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) in Combination with Methotrexate to Increase Response Rates and Duration of Therapy
Jun 12, 2019 08:11AM Horizon Pharma (HZNP) Highlights Systemic Implications of Gout and Need for Improved Patient Care Strategies at EULAR
Jun 12, 2019 08:00AM Horizon Therapeutics plc Highlights the Systemic Implications of Gout and the Need for Improved Patient Care Strategies with a Series of Presentations at EULAR 2019
Jun 4, 2019 08:00AM Horizon Therapeutics plc to Participate in the JMP Securities Life Sciences Conference
May 29, 2019 08:00AM Horizon Therapeutics plc and Invitae Corporation Launch Urea Cycle Disorder Genetic Testing Program
May 21, 2019 01:30PM Horizon Named One of the Best Workplaces in Chicago by Great Place to Work® and FORTUNE
View More Recent Stories View Older Stories